top of page
insurers_hero.jpg

Our Communities

Insurers

Nearly 50%

of lung cancer patients undergo multiple biopsies, increasing costs by 20-100%.¹ 

NGS testing can

save $740

per medicare patient compared to single gene testing.²

Earlier Detection. Protect Lives. Reduce Costs.
Everyone deserves to live longer healthier and with greater peace of mind.
Lucence provides innovative NGS solutions that can transform healthcare to be earlier, personalized and cost-effective.

Our solution for cancer detection and monitoring

  • liquidhallmark_hero.jpg

    LiquidHALLMARK is an ultrasensitive blood test designed to detect tumor-derived ctDNA and ctRNA to identify cancer-related mutations and biomarkers with a single blood draw.

    LiquidHALLMARK is currently Medicare covered under CPT code 0571U for qualifying patients with advanced cancer.

Lucence is collaborating with Mayo Clinic Laboratories to expand access to LiquidHALLMARK testing.
LiquidHALLMARK has been added to Mayo Clinic Laboratories test catalog.

Patient Stories

Real case. Real insights.

Learn how our solutions have supported patients worldwide.

crosslink_patientstories.jpg

Frequently Asked Questions

  • The test may be useful when tissue biopsy is not feasible due to insufficient tissue quantity, or inaccessible tumor location.

    In our LIQUIK study, when tissue NGS was negative for NCCN guideline-recommended biomarkers (46/151), liquid biopsy detected 7 patients with actionable biomarkers.

    When tissue NGS could not be performed (e.g. quantity not sufficient) (31/151), liquid biopsy detected actionable biomarkers in 48.4% of patients (15/31).

    LiquidHALLMARK also showed 93-100% concordance with tissue NGS for 9 NCCN guideline-recommended biomarkers (EGFR, ALK, RET, ROS1, BRAF, KRAS, MET, ERBB2, and NTRK1/2/3).

    Read the full publication

  • LiquidHALLMARK combines ctDNA and ctRNA analysis, enabling high sensitivity for detecting fusions and other alterations often missed by ctDNA-only panels.

    In our LIQUIK study, LiquidHALLMARK ctDNA + ctRNA detected 15.6% (52/68 vs 45/68) additional tissue-confirmed, NCCN guideline-recommended biomarkers for NSCLC than the ctDNA-only
    FDA-approved test.

    Read the full publication

  • LiquidHALLMARK is currently not FDA approved. However combined DNA and RNA testing is recommended in the NCCN guidelines to maximise detection of actionable fusions in NSCLC patients.

    LiquidHALLMARK testing is conducted at our CLIA-certified and CAP-accredited laboratory in Palo Alto.  

  • LiquidHALLMARK is designed to detect guideline-recommended cancer biomarkers - including RNA fusions that are often missed by ctDNA-only liquid biopsy tests. 

    LiquidHALLMARK can be done at time of diagnosis for therapy selection, clinical trial matching and at follow-up for monitoring to guide therapy adjustments.

References:

  1. Zheng, Feibi et al. Journal of medical economics vol. 24,1 (2021): 1173-1177.

  2. Mirza, Myriam et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 27,9 (2024): 1300-1309.

bottom of page